ICCC vs IDXX vs NWPX Stock Comparison

Immucell, Idexx Laboratories and NWPX Infrastructure Prices as of Oct 29, 2026 Peers: Industry group
ICCC Immucell Corp /De/
$10.32 +3.8% 1M +71.1% 1Y
Market cap
$93.87M
P/E
–
Revenue (TTM)
$26.76M
Div. yield
–
Animal Health Healthcare
1 win

Head to Head

11 decided of 12

NWPX Infrastructure leads on 6 of the 12 questions below (NWPX Infrastructure 6, Idexx Laboratories 4, Immucell 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionICCCIDXXNWPXLeader
Larger companyMarket capitalisation $93.87M $43.52B $933.58M IDXX
Cheaper on earningsLower P/E, profitable companies only -143.9x 38.2x 17.5x NWPX
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 36.9x 18.9x NWPX
Faster revenue growthRevenue growth, trailing twelve months -5.3% +12.8% +15.9% NWPX
More profitableNet margin, trailing twelve months -2.4% 25.0% 8.9% IDXX
Better return on capitalReturn on invested capital 6.5% 45.6% 12.5% IDXX
Less leveragedLower net debt / EBITDA -0.1x 0.5x 0.2x ICCC
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +71.1% -8.2% +76.0% NWPX
Better 5-year returnAnnualised price return, 5 years +3.2%/yr -2.9%/yr +32.8%/yr NWPX
Less volatileAnnualised volatility, 1 year 50.5% 32.1% 40.0% IDXX
Higher overall scoreMean of the five percentile scores vs peers 73/100 77/100 80/100 NWPX

Percentile Scorecard

ICCCIDXXNWPX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisICCCIDXXNWPX
Valuation 86 #89 of 624 75 #155 of 624 100 #1 of 21
Growth 65 #209 of 601 76 #148 of 601 94 #2 of 19
Profitability 83 #92 of 541 97 #17 of 541 80 #4 of 16
Financial Health 58 #273 of 647 46 #350 of 647 70 #7 of 21
Shareholder Returns – 93 #26 of 359 56 #5 of 10
Overall 73 77 80
  • ICCC ranked among 671 companies in Pharmaceuticals and Biotechnology
  • IDXX ranked among 671 companies in Pharmaceuticals and Biotechnology
  • NWPX ranked among 22 companies in Environmental Equipment

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodICCCIDXXNWPXSPY
1 month +3.8%+8.0%-4.3% +0.7%
3 months -6.7%+3.1%-22.8% +3.7%
6 months +22.0%+2.7%-0.3% +7.1%
Year to date +67.8%-14.9%+56.8% +12.8%
1 year +71.1%-8.2%+76.0% +11.9%
3 years +109.3%+45.3%+253.8% +85.2%
3 years, per year +27.9%+13.3%+52.4% +22.8%
5 years +17.3%-13.5%+312.5% +67.6%
5 years, per year +3.2%-2.9%+32.8% +10.9%
10 years +83.3%+448.3%+647.0% +262.0%
10 years, per year +6.2%+18.6%+22.3% +13.7%

Risk

MeasureICCCIDXXNWPXSPY
Volatility, 1Y 50.5%32.1%40.0% 12.7%
Downside volatility, 1Y 47.6%31.3%34.4% 12.6%
Beta vs S&P 500, 1Y 0.410.791.30 1.00
Return / volatility, 1Y 1.41-0.261.90 0.94
Max drawdown, 5Y -67.0%-51.3%-35.8% -25.4%
From 52-week high -11.9%-24.9%-34.6% -1.2%
52-week high $11.72$766.68$149.94 $779.14
52-week low $4.56$504.70$53.85 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleICCCIDXXNWPX
P/E now vs peer median -143.4xmedian 17.8x 39.9xmedian 17.8x 17.7xmedian 25.4x
P/S now vs peer median 3.5xmedian 9.1x 10.0xmedian 9.1x 1.6xmedian 2.5x
EV/EBITDA now vs peer median 18.3xmedian 15.0x 28.6xmedian 15.0x 10.3xmedian 17.9x
P/FCF now vs peer median —median 21.7x 36.2xmedian 21.7x 10.9xmedian 22.3x
P/B now vs peer median 3.0xmedian 2.2x 28.2xmedian 2.2x 2.2xmedian 1.8x
PEG now vs peer median -2.61median 0.35 2.64median 0.35 0.54median 1.73

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsICCCIDXXNWPX
Revenue $26.76M $4.55B $602.76M
Gross profit $10.53M $2.84B $125.97M
Operating income $2.47M $1.46B $71.15M
Net income -$652.35K $1.14B $53.48M
Free cash flow – $1.25B $86.83M
R&D $2.40M $261.47M –
EPS (diluted) $-0.07 $14.37 $5.45
Cash & equivalents $8.86M $196.93M $6.06M
Total debt $8.30M $968.86M $21.50M
Shares (diluted) 9.19M 79.31M 9.81M
Enterprise value $71.31M $42.73B $891.67M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricICCCIDXXNWPX
P/E -143.4x 39.9x 17.7x
P/FCF – 36.2x 10.9x
P/Operating cash flow – 33.1x 8.8x
P/S 3.5x 10.0x 1.6x
P/B 3.0x 28.2x 2.2x
P/Tangible book 3.0x 30.0x 2.3x
EV/EBITDA 18.3x 28.6x 10.3x
EV/EBIT 37.8x 31.7x 13.5x
EV/Revenue 3.5x 10.1x 1.6x
EV/FCF – 36.8x 11.0x
EV/Operating cash flow – 33.7x 9.0x
PEG (3Y EPS CAGR) -2.61 2.64 0.54

Growth

14 metrics
MetricICCCIDXXNWPX
Revenue growth (1Y) -5.3% 12.8% 15.9%
Revenue CAGR (3Y) 19.5% 9.0% 11.0%
Gross profit growth (1Y) -0.6% 14.4% 26.8%
Gross profit CAGR (3Y) 36.0% 10.5% 16.2%
Operating income growth (1Y) 42.3% 16.2% 47.2%
Operating income CAGR (3Y) 34.3% 11.7% 25.2%
Net income growth (1Y) -137.0% 15.6% 46.0%
Net income CAGR (3Y) 52.3% 12.9% 31.4%
EPS growth (1Y) -136.4% 18.1% 46.1%
EPS CAGR (3Y) 55.0% 15.1% 32.7%
Operating cash flow growth (1Y) – 51.4% 58.5%
Operating cash flow CAGR (3Y) – 22.5% 43.1%
Free cash flow growth (1Y) – 59.9% 80.1%
Free cash flow CAGR (3Y) – 28.4% 92.6%

Profitability

14 metrics
MetricICCCIDXXNWPX
Gross margin 39.3% 62.4% 20.9%
EBITDA margin 19.0% 35.4% 15.4%
Operating margin 9.2% 32.0% 11.8%
Pretax margin -2.2% 31.3% 11.4%
Net margin -2.4% 25.0% 8.9%
FCF margin – 27.5% 14.4%
Operating cash flow margin – 30.1% 17.7%
Return on equity -2.2% 71.9% 12.5%
Return on assets -1.5% 33.4% 7.9%
Return on invested capital 6.5% 45.6% 12.5%
Return on capital employed 6.1% 68.6% 12.9%
Asset turnover 0.6x 1.3x 0.9x
Cash conversion (OCF / net income) – 1.2x 2.0x
Stock comp / revenue 1.8% 1.4% 1.2%

Financial Health

11 metrics
MetricICCCIDXXNWPX
Debt / assets 17.8% 28.1% 3.1%
Debt / equity 0.3x 0.6x 0.0x
Net debt / EBITDA -0.1x 0.5x 0.2x
Debt / FCF – 0.8x 0.2x
Liabilities / assets 32.7% 53.2% 37.0%
Equity / assets 67.3% 46.8% 63.0%
Interest coverage 5.3x 38.6x 48.6x
Current ratio 4.8x 1.2x 2.6x
Quick ratio 2.7x 0.7x 1.8x
Cash ratio 2.0x 0.2x 0.0x
Altman Z-score 4.52 20.55 4.40

Shareholder Returns

7 metrics
MetricICCCIDXXNWPX
Dividend yield – – –
Net buyback yield – 2.3% 0.7%
Shareholder yield – 2.3% 0.7%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusICCCIDXXNWPX
Forward P/E – 36.9xFY2026 18.9xFY2026
EPS, next fiscal year – $15.63FY2026 $5.19FY2026
EPS growth, next FY – +19.5%FY2026 +45.8%FY2026
EPS growth, the year after – +12.9% -7.5%
Revenue, next fiscal year – $5.00BFY2026 $573.90MFY2026
Revenue growth, next FY – +16.3%FY2026 +9.1%FY2026
Revenue growth, the year after – +0.6% +3.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersICCCIDXXNWPX
Held by institutions 15.0% 93.6% 89.5%
Institutions holding 32 1,290 225
Change in shares held, QoQ -2.6% +4.1% +4.6%
Institutions buying 15 588 125
Institutions selling 7 496 65
Buyers to sellers 2.14 1.19 1.92

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ICCCIDXXNWPX
ICCC 1.00 0.05 0.10
IDXX 0.05 1.00 0.13
NWPX 0.10 0.13 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ICCC, IDXX and NWPX?

Idexx Laboratories (IDXX) is the largest by market capitalisation: Immucell (ICCC) $93.87M, Idexx Laboratories (IDXX) $43.52B, NWPX Infrastructure (NWPX) $933.58M.

Which stock is cheaper, ICCC, IDXX and NWPX?

NWPX Infrastructure (NWPX) trades on the lowest price-to-earnings ratio (Immucell (ICCC) -143.9x, Idexx Laboratories (IDXX) 38.2x, NWPX Infrastructure (NWPX) 17.5x). On next year's consensus earnings, NWPX Infrastructure (NWPX) is cheapest (Idexx Laboratories (IDXX) 36.9x, NWPX Infrastructure (NWPX) 18.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

NWPX Infrastructure (NWPX) grew revenue fastest over the trailing twelve months: Immucell (ICCC) -5.3%, Idexx Laboratories (IDXX) +12.8%, NWPX Infrastructure (NWPX) +15.9%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Immucell (ICCC) -2.4%, Idexx Laboratories (IDXX) 25.0%, NWPX Infrastructure (NWPX) 8.9%). On return on invested capital, Idexx Laboratories (IDXX) leads (Immucell (ICCC) 6.5%, Idexx Laboratories (IDXX) 45.6%, NWPX Infrastructure (NWPX) 12.5%).

Which stock has performed better?

Over the past year NWPX Infrastructure (NWPX) returned the most: Immucell (ICCC) +71.1%, Idexx Laboratories (IDXX) -8.2%, NWPX Infrastructure (NWPX) +76.0%. Over five years, NWPX Infrastructure (NWPX) compounded fastest (Immucell (ICCC) +3.2%/yr, Idexx Laboratories (IDXX) -2.9%/yr, NWPX Infrastructure (NWPX) +32.8%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Idexx Laboratories (IDXX) has been the steadiest (Immucell (ICCC) 50.5%, Idexx Laboratories (IDXX) 32.1%, NWPX Infrastructure (NWPX) 40.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ICCC, IDXX and NWPX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, NWPX Infrastructure (NWPX) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.